Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: Human Immunodeficiency Virus
Interventions: brentuximab vedotin, Placebo, ART; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: San Francisco, California • Chicago, Illinois

Conditions: PAH
Interventions: 75mg CXA-10, 150mg CXA-10, Placebo; Drug · Other
Lead sponsor: Complexa, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more

Conditions: Healthy
Interventions: Placebo, Flavonoids, Flavonoids+Prebiotics; Other · Dietary Supplement
Lead sponsor: Pharmanex; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Logan, Utah

Conditions: Menkes Disease, Occipital Horn Syndrome
Interventions: Droxidopa, Placebo; Drug · Other
Lead sponsor: Stephen G. Kaler, MD; Other
Eligibility: 18 Years to 50 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Biliary Cholangitis
Interventions: Elafibranor, Placebo; Drug · Other
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 20
States / cities: Coronado, California • Los Angeles, California • Sacramento, California + 16 more

Conditions: Muscular Injury
Interventions: Turmeric Strength for Joint, Placebo; Dietary Supplement
Lead sponsor: Appalachian State University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Kannapolis, North Carolina

Conditions: Asthma
Interventions: Albuterol dry powder inhaler, Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler); Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Lakewood, Colorado + 5 more

Conditions: Obesity, Schizophrenia, Schizoaffective Disorder
Interventions: Naltrexone 25mg, Placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Adults
Interventions: Beetroot juice, Placebo drink; Dietary Supplement
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: mipomersen sodium, moxifloxacin hydrochloride (Avelox®), placebo; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Sickle Cell Disease, Vaso-occlusive Pain Episode
Interventions: L-arginine, L-arginine Loading Dose, Placebo; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 3 Years to 21 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Scoliosis Correction, Iron Deficiency, Transfusion Blood, Surgery Complications, Spinal Fusion, Scoliosis Idiopathic Adolescent, Scoliosis Neuromuscular
Interventions: Ferric carboxymaltose IV, Normal Saline (Placebo); Drug
Lead sponsor: Columbia University; Other
Eligibility: 10 Years to 19 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 935 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 92
States / cities: Cullman, Alabama • Jasper, Alabama • Scottsboro, Alabama + 79 more

Conditions: Asthma
Interventions: omalizumab, Placebo; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Coronary Syndrome, Fear, Medication Adherence
Interventions: Cognitive Bias Modification Training, Attention Control Training; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Naltrexone HCl 50 MG Oral Tablet, Placebo
Interventions: Naltrexone Oral Product, Placebo; Drug
Lead sponsor: Texas Tech University; Other
Eligibility: 18 Years to 120 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Osteoarthritis
Interventions: naproxen, CE-224535, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 46
States / cities: Anniston, Alabama • Bayou La Batre, Alabama • Birmingham, Alabama + 39 more

Conditions: Tobacco Use Disorder, Schizophrenia
Interventions: sensorimotor replacement, 42 mg transdermal nicotine replacement, Placebo transdermal nicotine, usual brand smoking; Behavioral · Drug · Other
Lead sponsor: Brown University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Hereditary Angioedema (HAE)
Interventions: navenibart, Placebo; Drug
Lead sponsor: Astria Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 15 more

Conditions: Nicotine Withdrawal, Marijuana Dependence, Cannabis Dependence, Nicotine Dependence, Cannabis Abuse
Interventions: Placebo Aprepitant, Active Aprepitant; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 45 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Charlottesville, Virginia

Conditions: Proteinuric Kidney Disease
Interventions: VX-147, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 10 Years to 65 Years
Enrollment: 522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 223
States / cities: Alabaster, Alabama • Birmingham, Alabama • Fairhope, Alabama + 144 more

Conditions: HIV Infections
Interventions: BMS-936559, Placebo for BMS-936559; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Aurora, Colorado • St Louis, Missouri • Chapel Hill, North Carolina + 2 more

Conditions: Colitis, Ulcerative
Interventions: Guselkumab Dose 1, Guselkumab Dose 2, Golimumab Dose 1, Golimumab Dose 2, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 14
States / cities: San Diego, California • Colorado Springs, Colorado • Tampa, Florida + 11 more

Conditions: Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)
Interventions: High-Resistance Breathing and Drinking Exercises, Low-Resistance Breathing and Drinking Exercises; Behavioral
Lead sponsor: Uniformed Services University of the Health Sciences; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

A Safety Study of Brentuximab Vedotin in Participants With HIV

PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)

Effect of a Proprietary Dietary Supplement on Fecal Volatile Organic Compounds

NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome

A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

Turmeric and Exercise-Induced Muscle Damage and Oxinflammation

A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)

Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia

Effect of Acute Nitrate Supplementation on Vascular Function in Hispanic, Black and White Population

A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects

Arginine Therapy for Sickle Cell Disease Pain

IntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation

Effect of Anti-IgE in Non-Allergic Asthma

Investigating Fear Of Recurrence as a Modifiable Mechanism of Behavior Change

Naltrexone for Prolonged Grief Disorder

A Study Of The Effect Of CE-224535 On Knee OA (Osteoarthritis) Pain

Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia

A Study of Navenibart in Participants With Hereditary Angioedema

Medications Development for the Treatment of Cannabis Related Disorders

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy

A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Low-Tech Treatments for Obstructive Sleep Apnea